Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cipher Mining Inc (CIFR) vs Mesoblast Limited (MESO) Price & Performance

Cipher Mining IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Cipher Mining Inc vs Mesoblast Limited — how do they compare? Cipher Mining Inc trades at $17.94 (market cap $7.14B), while Mesoblast Limited trades at $16.86 (market cap $2.21B). The key difference: Cipher Mining Inc is far larger — about 3.2× Mesoblast Limited's market cap. Which is the better fit depends on your goals.

CIFRMESO
Market Cap
$7.14B$2.21B
Sector
Basic MaterialsTechnology
52-Week High
$29.18$20.96
52-Week Low
$4.72$12.88
Enterprise Value
$11.90B$2.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cipher Mining Inc

CIFR trades at $17.74, up 8.63% in the last session, but remains in a bearish technical trend with key support at $16. The company is transitioning from Bitcoin mining to AI data centers, reporting a Q2 2026 loss per share of $0.65, missing estimates. Revenue was $224 million in 2025 but fell to $191 million in 2026, with a net loss widening to $1.1 billion. Despite negative profitability metrics, analyst consensus is unanimously bullish with a $31.78 price target.

The outlook hinges on successful execution of its AI infrastructure pivot, offering growth potential but carrying high risk due to persistent losses, heavy capital expenditure, and reliance on project financing. Investors face volatility from operational cash burn and competitive pressures in the data center market, warranting caution despite optimistic Wall Street ratings.

Mesoblast Limited

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Returns comparison

Trailing returns across standard periods

About Cipher Mining Inc

Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.

Read more on CIFR

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO